IU421
发表于 2025-3-21 18:34:30
书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy影响因子(影响力)<br> http://impactfactor.cn/if/?ISSN=BK0181820<br><br> <br><br>书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy影响因子(影响力)学科排名<br> http://impactfactor.cn/ifr/?ISSN=BK0181820<br><br> <br><br>书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy网络公开度<br> http://impactfactor.cn/at/?ISSN=BK0181820<br><br> <br><br>书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy网络公开度学科排名<br> http://impactfactor.cn/atr/?ISSN=BK0181820<br><br> <br><br>书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy被引频次<br> http://impactfactor.cn/tc/?ISSN=BK0181820<br><br> <br><br>书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy被引频次学科排名<br> http://impactfactor.cn/tcr/?ISSN=BK0181820<br><br> <br><br>书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy年度引用<br> http://impactfactor.cn/ii/?ISSN=BK0181820<br><br> <br><br>书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy年度引用学科排名<br> http://impactfactor.cn/iir/?ISSN=BK0181820<br><br> <br><br>书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy读者反馈<br> http://impactfactor.cn/5y/?ISSN=BK0181820<br><br> <br><br>书目名称Bayesian Adaptive Design for Immunotherapy and Targeted Therapy读者反馈学科排名<br> http://impactfactor.cn/5yr/?ISSN=BK0181820<br><br> <br><br>
Meander
发表于 2025-3-21 23:31:13
Bayesian Adaptive Design for Immunotherapy and Targeted Therapy978-981-19-8176-0
考博
发表于 2025-3-22 03:39:06
https://doi.org/10.1007/978-981-19-8176-0Adaptive clinical trial design; Delayed outcomes; Late-onset outcomes; Markov Chain Monte Carlo (MCMC)
Acetaldehyde
发表于 2025-3-22 06:03:28
http://reply.papertrans.cn/19/1819/181820/181820_4.png
Connotation
发表于 2025-3-22 09:09:29
http://reply.papertrans.cn/19/1819/181820/181820_5.png
forecast
发表于 2025-3-22 12:53:40
http://reply.papertrans.cn/19/1819/181820/181820_6.png
Incorruptible
发表于 2025-3-22 17:38:15
http://reply.papertrans.cn/19/1819/181820/181820_7.png
AGATE
发表于 2025-3-23 01:07:21
Human Autonomy in Cross-Cultural Contextal., 2014), a Bayesian phase I/II design for immunotherapy (Liu et al., 2018), and an isotonic design (Zang et al., 2014). These designs assume a dose-toxicity and dose-efficacy model, and continuously update the estimate of the model in a way similar to the continual reassessment method (CRM). The
土坯
发表于 2025-3-23 02:23:48
https://doi.org/10.1007/978-3-031-05871-4e challenging to implement in practice. This chapter introduces two model-assisted phase I/II designs, BOIN12 and U-BOIN, to find the optimal biological dose (OBD). These two designs simultaneously consider toxicity and efficacy, and use the utility to quantify the risk-benefit tradeoff. Based on th
sed-rate
发表于 2025-3-23 08:54:59
https://doi.org/10.1007/978-981-15-2109-6III trials, using small sample sizes. This chapter first presents Simon’s two-stage design; and then introduces several novel Bayesian designs, including posterior probability (PrP) and predictive probability (PreP) approaches, and Bayesian optimal Phase II design (BOP2) and its extensions. Bayesian